Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies

Inan, Hakan; Wang, Shuqi; İnci, Fatih; Baday, Murat; Zangar, Richard C.; Kesiraju, Sailaja; Anderson, Karen S.; Cunningham, Brian T.; Demirci, Utkan

doi:10.1038/s41598-017-02672-6

Cited by 28 publications

(25 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…, exposure rate to high-risk HPV types), a variety of methods was developed for these purposes [35]. The studies showed that the anti-HPV16 E7 antibody could be used as a blood biomarker for HPV infections [4]. Moreover, antibodies against HPV virus-like particles (VLPs) were considered as a marker of HPV infection, and were associated with HPV-related disease, but not as strongly as E6 and E7 antibodies [36].…”

Section: Discussionmentioning

confidence: 99%

“…Among the high-risk HPVs, types 16 and 18 are responsible for the majority of cervical cancer in the world especially in Iran [1, 3]. The persistent HPV infections generate E6 and E7 oncoproteins which promote cell proliferation and carcinogenesis leading to increased levels of host antibodies [4]. As known, HPV DNA test along with routine Pap smear could reduce colposcopy rate in ASCUS patients [5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women

et al. 2019

View full text Add to dashboard Cite

BackgroundAmong different types of human papillomavirus (HPV), types 16 and 18 were known to be high-risk agents causing mainly cervical cancer. Up to now, the potential of HPV E7 protein has been proved as a diagnostic marker of cervical cancer. Moreover, the levels of anti-heat shock protein (Hsp) and anti-high mobility group box-1 (HMGB1) antibodies in cancer patients have been useful in tumor diagnosis. The goal of the present study was to determine the efficiency of the potential serologic markers including HPV E7, Hsp20, Hsp27 proteins and Hp91 peptide in Iranian HPV-exposed women, for the first time.MethodsAt first, the recombinant HPV E7, Hsp20 and Hsp27 proteins were expressed in E. coli system, and purified by affinity chromatography under native conditions. Then, antibody responses were detected against the recombinant proteins as well as Hp91 peptide as potential markers in 49 Iranian women who were seropositive for HPV-16 and 18 L1 capsids (i.e., HPV-exposed women) and 49 controls using indirect ELISA.ResultsOur data indicated that the seroreactivities of women exposed to HPV16, HPV18 and both of them against the recombinant E7, Hsp20, Hsp27 proteins and Hp91 peptide were significantly higher than those in control group (p < 0.05 for HPV16 or HPV18; p < 0.01 for both of them versus all markers). HPV-exposed women with high antibody responses to HPV-16 and 18 L1 capsids as a commercial biomarker had significant seroreactivity to HPV-16 and 18 E7 and Hsp27 (p < 0.05). The recombinant E7 and Hsp27 proteins showed higher efficiency than Hsp20 and Hp91 for detection of individuals exposed to HPV infections (p < 0.05).ConclusionGenerally, the levels of serum E7 and Hsp27 were increased in HPV-16 and 18 L1- seropositive women suggesting their potential value as a diagnostic marker for HPV infections.Electronic supplementary materialThe online version of this article (10.1186/s12879-019-3780-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Microfluidic devices provide various advantages over conventional plate-based microwells for diagnostic tests such as blood separation and cell count. [40] Such advantages include, precise control of sample volume with minuscule amount, wide range of geometries mimicking the biological environment, and ability to expose the biological moieties to shear stress using flow thus mimicking their natural environment. [41,42]…”

Section: Discussionmentioning

confidence: 99%

Monitoring Neutropenia for Cancer Patients at the Point of Care

et al. 2017

Self Cite

View full text Add to dashboard Cite

Neutrophils have a critical role in regulating the immune system. The immune system is compromised during chemotherapy, increasing infection risks and imposing a need for regular monitoring of neutrophil counts. Although commercial hematology analyzers are currently used in clinical practice for neutrophil counts, they are only available in clinics and hospitals, use large blood volumes, and are not available at the point of care (POC). Additionally, phlebotomy and blood processing require trained personnel, where patients are often admitted to hospitals when the infections are at late stage due to lack of frequent monitoring. Here, a reliable method is presented that selectively captures and quantifies white blood cells (WBCs) and neutrophils from a finger prick volume of whole blood by integrating microfluidics with high-resolution imaging algorithms. The platform is compact, portable, and easy to use. It captures and quantifies WBCs and neutrophils with high efficiency (>95%) and specificity (>95%) with an overall 4.2% bias compared to standard testing. The results from a small cohort of patients (N = 11 healthy, N = 5 lung and kidney cancer) present a unique disposable cell counter, demonstrating the ability of this tool to monitor neutrophil and WBC counts within clinical or in resource-constrained environments.

show abstract

“…They validated the nanosensor in serum samples and supplied high responses as compared with control samples. They showed that this nanosensor can be implemented as a pretesting tool to diagnose for broad monitoring of HPV-associated cancers [84]. Teengam et al reported a colorimetric nanosensor to screen synthetic HPV.…”

Section: Human Papillomavirusmentioning

confidence: 99%